KI-67 PROLIFERATING INDEX AND HISTOLOGICAL GRADE, TYPE AND STAGE OF COLORECTAL CARCINOMA

Authors

  • Uzma Nabi
  • A H Nagi
  • Waqas Sami

Abstract

Background: The objective of this study was to assess the relationship of histological type, grade andstage of colorectal carcinoma with proliferative activity as measured by Ki-67 LI. It was a descriptivestudy and conducted at the Department of Pathology, University of Health Sciences, Lahore. Methods:Ki-67 is a protein associated with cell proliferation and is expressed in all the phases of cell cycle exceptG0. In the present study, Ki-67 expression in 50 patients with colorectal adenocarcinomas was observedusing immunohistochemistry with monoclonal antibody MIB-1. Results: Ki-67 LI was high in well andmoderately differentiated adenocarcinomas (mean Ki-67 LI 392.50± 56.58 and 342.24±96.84respectively) as compared to poorly differentiated adenocarcinomas (mean Ki-67 LI 250.00±113.46). Ki-67 LI was high in non mucinous adenocarcinomas than mucin secreting and signet ring celladenocarcinomas (mean Ki-67 393.93±55.91 vs 220.00±49.72 and 200.00±79.05 respectively). As regardthe Dukes’ staging, Ki-67 LI was high in colorectal carcinomas in Dukes’ stage B than tumours in Dukes’stage C (Mean Ki-67 LI 360.13±90.03 vs 241.66±101.31 respectively). Conclusion: The proliferativeactivity as measured by Ki-67 antibody is related to histological type, grade and stage.Keywords: Colorectal carcinoma, Grade, Proliferation index, Immunohistochemistry, Ki-67

References

Bisgaard LM. Young age colorectal cancer and identification

of hereditary non-polyposis colorectal cancer cohorts. Br J

Surg 2007;94:1055–6.

J Ayub Med Coll Abbottabad 2008;20(4)

http://www.ayubmed.edu.pk/JAMC/PAST/20-4/Uzma.pdf

Reza MM, Blasco AJ, Andradas E, Cantero R, Mayol J.

Systematic review of laparoscopic versus open surgery for

colorectal cancer. Br J Surg 2006;93:921–8.

Skjelbred F C, Sæbø M, Hjartaker A, Grotmol T, Hansteen LI,

Tveit MK, et al. Meat, vegetables and genetic polymorphisms

and the risk of colorectal carcinoma and adenomas. BMJ

Cancer 2007;7:228–34.

Soreide K, Janssen MAE, Soiland H, Korner.H, Baak APJ.

Microsatellite instability in colorectal cancer. Br J Surg

;93:395–406.

Conlin A, Smith G, Carey A. F, Wolf R. C, Steele CJR. The

prognostic significance of K-ras, p53, and APC mutations in

colorectal carcinoma. Gut 2005;54:1283–86.

Leslie A, Carrey FA, Pratt NR, Steele RJC. The colorectal

adenoma_carcinoma sequence. Br J Surg 2002;89:845–60.

Rosai J. Gastrointestinal tract In: Ackerman’s surgical

pathology. 9th ed. St. Louis: Mosby, 2004;p. 750–858.

Raraty MG, Winstanley JH. Variation in the staging of

colorectal carcinomas: a survey of current practice. Ann R Coll

Surg Engl 1998;80:188–91.

Gordon PH, Nivatvongs S. editors. Principles and practice of

surgery for the colon, rectum and anus. Missouri: Karen

Berger, 1992;p.503–20.

Oshima FTC, Iriya K, Forones MN. Ki-67 as a prognostic

marker in colorectal cancer but not in gastric cancer. Neoplasm

;5:420–4.

Urruticocechea A, Smith EI, Dowsett M. Proliferation Marker

Ki-67 in Early Breast Cancer. J Clin Oncol 2005;23:7212–20.

Bancroft J, Anderson G. Tissue Processing and Microtomy

including Frozen. In: Bancroft JD, Gamble M, editors. Theory

and practice of Histological techniques.5th ed. New York:

Churchill Livingstone, 2002; p. 85–107.

Key M. Immunohistochemical Staining Methods, 4th ed.

Avaiable from: http://pri.dako.com/08002_25may06_ihc_

guide_book.pdf

Saleh HA, Jackson H, Khatib G, Banerjee M. Correlation of

bcl-2 Oncoprotein Immunohistochemical Expression with

Proliferation Index and Histopathologic Parameters in

Colorectal Neoplasia. AppI Immunohistochem Mol Morphol

;8:175–82.

Valera. V, Yokoyama. N, Walter. B, Okamoto. H, Suda.T and

Hatakeyama. K. Clinical significance of Ki-67 proliferation

index in disease progression and prognosis of patients with

resected colorectal carcinoma.Br J Surg 2005;92:1002–7.

Ishida H, Sadahiro S, Suzuki T, Ishikawa K, Kamijo A, Tajima

T et al. Proliferative, infiltrative and metastatic activities in

colorectal tumours assessed by MIB-1 antibody. Oncology

;10:1741–5.

Lanza G Jr, Cavazzini L, Borghi L, Ferretti S ,Buccoliero F and

Rubbini M. Immunohistochemical assessment of growth

fraction in colorectal adenocarcinomas with monoclonal

antibody Ki-67. Relation to clinical and pathological variables.

Path Res Prac 1990;186:608–18.

Georgescu VC, Saftoiu A, Georgescu CC, Ciurea R, Ciurea T.

Correlation of Proliferation Markers, p53 expression and

Histological Findings in Colorectal carcinomas. J gastroenterol

and liver diseases 2007;16:125–9.

Jansson A, Sun XF. Ki-67 expression in relation to

clinicopathological variables and prognosis in colorectal

adenocarcinomas.APMIS 1997;9:730–4.

Shepherd AN, Richman IP, England J. Ki-67 derived

proliferative activity in colorectal adenocarcinoma with

prognostic correlations. J Pathol 1988;155:213–9.

Kyzer S, Gordon HP. Determination of proliferative activity in

colorectal carcinoma using monoclonal antibody Ki-67. Dis

Colon Rectum 1997;40:322–5.

Sahin AA, Ro JY, Brown RW, Ordonez NG, Cleary KR, el

Naggar AK, Assessment of Ki-67 derived tumour

proliferative activity in colorectal adenocarcinomas. Mod

Pathol 1994;1:17–22.

Petrowsky H, Sturm I, Graubitz O, Kooby AD, Staib-Sebler E,

Gog C et al. Relevance of Ki-67 antigen expression and K-ras

mutation in colorectal liver metastases. E J S O 2001;27:80–7.

.Michael-Robinson MJ, Reid EL, Puride MD, BiemerHuttmann EA, Walsh DM, Pandeeya N, et al. Proliferation

,Apoptosis and Survival in High Level Microsatellite

Instability Sporadic Colorectal Cancer. Clinical Cancer

Research 2001;7:2347–56.

Published

2008-12-01

Most read articles by the same author(s)